ECHO: context and limitations
The ECHO Trial Consortium found no statistically significant increase in risk of HIV acquisition for women using intramuscular injectable depot medroxyprogesterone acetate (DMPA-IM) compared with those using the copper intrauterine device or the levonorgestrel (LNG) implant. 1 In response, WHO revised their medical eligibility criteria, which are used to develop counselling materials for women, to indicate that DMPA-IM should have no restriction on its use. 2 However, this decision does not adequately reflect the totality of evidence available.
Interpreting trial results must be done in light of the study design. Ideally, DMPA-IM would have been compared with multiple contraceptive methods and non-inferiority should have been determined between each method. In ECHO, DMPA-IM was compared with two other methodswhich might or might not confer risk themselves-and was only powered to detect a hazard ratio (HR) equal to or greater than 1·5, even though previous observational studies suggested lower effects (HRs of about 1·4). 3, 4 The ECHO Consortium justified this design on the basis of a stakeholder consultation about a "meaningful difference that would inform policy change". 1 Such a relativistic approach allows important absolute increases in risk conferred by a method to be overlooked. After all, a 20% increase in risk matters very much to a woman if her absolute risk is already high, and the HIV incidence of 3·81 per 100 woman-years in ECHO is well above WHO's threshold of substantial risk. 5 Mathematical modelling of this level of risk indicates that an extra 5800 HIV infections could have occurred over the past 5 years in Uganda, a country with typical DMPA-IM use and typically high HIV prevalence for sub-Saharan Africa. This number of extra HIV infections is comparable with the number of infections pre-exposure prophylaxis might avert over the next 5 years in the same setting with typical shortterm use. The situation could be more extreme in contexts such as South Africa, where DMPA-IM use and HIV risk are higher than in Uganda.
We should be careful not to rely too much on the arbitrary threshold for p values to indicate statistical significance, 6 as highlighted in a recent commentary on ECHO. 7 Failing to find a statistically significant effect in a trial never implies evidence of no effect at all. We should be especially concerned about such inferences when the trial is underpowered, the trend is consistent with foregoing data, and the potential effect studied causes harm.
Therefore, we propose an interpretation of the ECHO result in the context of other data, including observational, animal, and in-vitro studies that have suggested a causal link between DMPA-IM and higher HIV acquisition risk. 3, 4, 8 One established way of synthesising evidence is with a Bayesian perspective, whereby information about the true underlying risk would be modified, but not fully determined by new evidence. A heuristic approach would be to use observational evidence as the Bayesian prior for the true HR, which when updated with the ECHO results and weighted towards the trial, might yield a posterior HR for DMPA-IM with a 95% credible range of 1·00-1·36. Regardless of the synthesis and weighting method, the appropriate interpretation is not that the trial results removed any possibility of risk, but that our posterior estimate of the effect has been moderated. Women should have access to such data, which It is useful to consider populationlevel HIV and reproductive health outcomes with different scenarios of future contraceptive use. We modelled four scenarios of changes in the contraceptive method mix relative to status quo in Uganda with potential HR values for DMPA-IM of 1·0-1·2 (figure; appendix pp 24-25). This model shows that, if women stopped using DMPA-IM from 2019 onwards without replacement by other methods, the impact on reproductive health (maternal mortality and morbidity, and mortality associated with unsafe abortions) would be detrimental irrespective of whether DMPA-IM increased HIV risk. The described scenario must be avoided. However, if other methods replace DMPA-IM, or overall contraceptive use is expanded, then net health is improved regardless of DMPA-IM's precise increase in HIV risk. Thus, the best way to manage a residual and unknown risk for DMPA-IM is to ensure a greater diversity in the contraceptive method mix, to give women comprehensive information about the risks, and to improve access to effective contraception. Now is the moment to increase women's choices of and access to contraceptives and not fall back to business as usual. BLJ, JAS, and TBH report grants from the Bill & Melinda Gates Foundation, during the conduct of the study. JAS also reports personal fees from the Gates Foundation and grants from United States Agency for International Development, outside the submitted work. All other authors declare no competing interests. The funder had no role in the design and interpretation of the work, or the decision to submit for publication. BLJ, JAS, and TBH acknowledge joint MRC Centre for Global Infectious Disease Analysis funding from the UK Medical Research Council and Department for International Development (MR/R015600/1). HEJ receives salary support from the Einstein-Rockefeller-CUNY Center
